|
The following is attributed to FDA Commissioner Stephen M. Hahn, M.D.
Emergency use authorizations, or EUAs, are an important tool in our country’s fight against COVID-19 and other public health emergencies. While EUAs have received increased attention during the COVID-19 public health emergency, EUAs are not a new tool to the FDA. I want to take a moment to reaffirm FDA’s commitment to transparency around the EUA process and share some updates on our plan to provide more information about FDA’s decisions to issue, revise or revoke EUAs for drugs and biological products, including vaccines.
Earlier this year, we launched the COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) to help apply best practices and lessons learned from the emergency response to date. Our goal is to optimize the ongoing COVID-19 response, while also strengthening our resilience and improving our capacity to respond to ...
|
|
|
|
